Medscape
WHO Guidance, GLP-1 Price Curbs Unlikely to Change Practice
A new WHO guideline on GLP-1s and recent efforts to reduce the drugs’ costs now and going forward are unlikely to change US ...
Fierce Biotech
Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M
Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug. At the heart of the deal is brelovitug, an immunoglobulin G1 monoclonal ...
Mirum to buy Bluejay for up to $820 million in bet on liver-disease drug
Mirum Pharmaceuticals said on Monday it will acquire Bluejay Therapeutics in a deal worth up to $820 million, adding a ...
BioPharma Dive
Mirum gains a hepatitis D drug in $620M buyout of startup Bluejay
The deal, which includes another $200 million in potential payouts, hands the California biotech a candidate in late-stage ...
FierceBiotech
Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key ...